Protagenic Therapeutics effects 1-for-14 reverse stock split to meet Nasdaq bid price rule

Protagenic Therapeutics, Inc.new

Reverse stock split at 1-for-14 ratio effective 12:01 a.m. ET on May 5, 2025.
Approved by stockholders at April 18, 2025 special meeting; board set ratio to comply with Nasdaq Rule 5550(a)(2).
Common stock trades on Nasdaq under symbol PTIX with new CUSIP 74365N301; warrants continue under PTIXW.
Fractional shares rounded up; proportionate adjustments to outstanding options, warrants, and RSUs.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Protagenic Therapeutics, Inc.new: Approved and filed a certificate of amendment to effect a 1-for-14 reverse stock split of common stock (effective 2025-05-05).

Change: charter amendment
Effective: 2025-05-05

Exact text from the filing

On May 2, 2025, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its third amended and restated certificate of incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

Protagenic Therapeutics, Inc.new filing history →

Source: SEC EDGAR

accession 0001641172-25-008455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.